MAP2K7 and colorectal carcinoma: The BEACON trial evaluated the combination of encorafenib with cetuximab (an EGFR inhibitor), and in some cases, binimetinib (a MEK inhibitor), in patients with metastatic CRC with BRAF V600E mutation.